Two investigational drugs for hepatitis C (HCV), both taken orally, combined effectively in difficult-to-treat patients without the use of pegylated interferon, researchers reported.
The drugs — faldaprevir and deleobuvir (plus ribavirin) — led to undetectable HCV 12 weeks after the end of treatment in 52% to 69% of patients, without the need for interferon, according to Stefan Zeuzem, MD, of the Johann Wolfgang Goethe University Medical Center in Frankfurt, Germany, and colleagues.
But efficacy was lower when investigators omitted the standard HCV drug ribavirin from the mix, Zeuzem and colleagues reported in the Aug. 15 issue of theNew England Journal of Medicine.
Michael Smith
MedPage Today
Read More